Ashwagandha: Clinical Evidence for Cortisol, Testosterone, and Adaptogenic Mechanisms

Ashwagandha (Withania somnifera) has accumulated strong clinical trial evidence for cortisol reduction, testosterone support, and stress adaptation. This practitioner-level review covers mechanisms, trials, dosing, and safety.

This article is written for healthcare practitioners and informed readers. It is not a substitute for individualised clinical advice. Consult a qualified naturopath or integrative practitioner before commencing supplementation.

Of all the botanical medicines that have crossed from traditional Ayurvedic practice into evidence-based integrative medicine, ashwagandha (Withania somnifera) has accumulated among the strongest bodies of human clinical trial data. Where many adaptogens remain supported primarily by in vitro and animal studies, ashwagandha's effects on cortisol, testosterone, thyroid hormones, and cognitive function have been examined in multiple randomised controlled trials — making it one of the more tractable botanical medicines for practitioners who require mechanistic grounding and replicable outcomes data before integrating a compound into clinical practice.

This practitioner-level review covers the active constituents, proposed mechanisms of action, key RCT evidence across multiple domains, extract standardisation and dosing, and the safety and interaction profile relevant to naturopathic and integrative prescribing in Australia.

1. The Ayurvedic Adaptogen and Modern Evidence

Withania somnifera — commonly known as ashwagandha, Indian ginseng, or winter cherry — is a member of the Solanaceae family and has been used in Ayurvedic medicine for over 3,000 years. In classical texts including the Charaka Samhita and Sushruta Samhita, it is classified as a rasayana — a rejuvenating tonic indicated for longevity, vitality, and the restoration of depleted constitution.

The plant's primary bioactive compounds are the withanolides — a class of steroidal lactones found predominantly in the root, with withanolide A, withaferin A, withanone, and withanolide B being the most pharmacologically characterised. Total withanolide content in commercial extracts varies considerably; standardised extracts (KSM-66, Sensoril) define their bioactivity by withanolide percentage, making this figure the key quality marker practitioners should examine when assessing products.

The term "adaptogen" — coined by Soviet pharmacologist Nikolai Lazarev in 1947 and later operationalised by Israel Brekhman — describes substances that non-specifically increase resistance to physical, chemical, and biological stressors without disturbing normal physiological function. Ashwagandha meets these criteria across multiple biological domains. Unlike stimulant-based stress management, its mechanisms operate primarily through neuroendocrine normalisation rather than sympathetic activation.

Modern interest in ashwagandha's adaptogenic properties accelerated when human RCTs began producing statistically significant and clinically meaningful reductions in validated stress biomarkers — most notably serum cortisol. That evidence base, now spanning over a decade of controlled trials, forms the core of this review.

2. Mechanisms of Action

Understanding ashwagandha's mechanisms is essential for rational prescribing and for explaining to patients why effects accumulate over weeks rather than hours. Multiple overlapping pathways have been identified.

HPA Axis Modulation and Cortisol

The hypothalamic-pituitary-adrenal (HPA) axis is the primary neuroendocrine stress response system. Under chronic psychological or physiological stress, sustained CRH → ACTH → cortisol signalling produces the downstream consequences familiar to integrative practitioners: sleep disruption, immune suppression, hyperglycaemia, fat deposition, and reproductive hormone interference.

Withanolides appear to modulate HPA axis reactivity through several routes. Animal studies suggest effects at the level of the hypothalamus, reducing CRH release and downstream ACTH secretion. Withanolide A has demonstrated direct glucocorticoid receptor modulation in vitro, potentially influencing cortisol feedback sensitivity. Additionally, ashwagandha appears to reduce activity of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) — the enzyme responsible for local cortisol regeneration from inactive cortisone in peripheral tissues including adipose and liver. Inhibition of 11β-HSD1 reduces tissue-level cortisol exposure independent of serum levels, with implications for metabolic cortisol effects that would not be detected by serum testing alone.

Testosterone: LH/FSH Signalling

Ashwagandha's effects on testosterone appear to operate through the hypothalamic-pituitary-gonadal (HPG) axis. Under chronic stress, elevated cortisol suppresses gonadotropin-releasing hormone (GnRH) pulsatility, reducing luteinising hormone (LH) and follicle-stimulating hormone (FSH) secretion, and thereby impairing Leydig cell testosterone synthesis and Sertoli cell spermatogenesis. By reducing HPA axis hyperactivity and cortisol burden, ashwagandha may secondarily restore LH signalling and HPG axis function.

Some preclinical data also suggests direct effects on testicular steroidogenesis via antioxidant mechanisms — withanolides have demonstrated ROS-scavenging activity in testicular tissue in animal models, potentially protecting Leydig cell integrity and steroidogenic enzyme function.

GABA-Mimetic Neuroprotection

Withanolide A and withanone have demonstrated affinity for GABA-A receptor subunits in neuronal tissue, with anxiolytic and sleep-promoting effects observed in animal studies consistent with GABAergic activity. This mechanism is relevant to ashwagandha's well-documented improvements in subjective stress, anxiety, and sleep quality — effects that appear too rapid (within 2–4 weeks in some studies) to be entirely explained by HPA axis normalisation alone.

NF-kB Anti-Inflammatory Pathway

Withaferin A is a potent inhibitor of nuclear factor kappa B (NF-kB) — a master transcription factor regulating pro-inflammatory cytokine production (TNF-α, IL-6, IL-1β). In conditions of chronic low-grade inflammation, NF-kB hyperactivation sustains the inflammatory burden that perpetuates HPA axis dysregulation (via inflammatory cytokines stimulating CRH release). Ashwagandha's anti-inflammatory action thus intersects with and reinforces its cortisol-lowering effects.

Thyroid Hormone Conversion: T4 → T3

Ashwagandha appears to upregulate thyroid hormone production and the peripheral conversion of thyroxine (T4) to the active triiodothyronine (T3). The proposed mechanism involves stimulation of thyroid-stimulating hormone (TSH) responsiveness and enhanced deiodinase activity. Clinically, this effect has been observed in patients with subclinical hypothyroidism and is discussed further in Section 5. The thyroid mechanism warrants specific attention in patients on thyroid medication and in those with hyperthyroidism.

Mitochondrial and Energetic Pathways

Emerging research suggests ashwagandha supports mitochondrial function through antioxidant enzyme upregulation (superoxide dismutase, catalase, glutathione peroxidase) and potential AMPK activation. AMPK is also the primary cellular switch that initiates autophagy — and ashwagandha's cortisol-lowering effects are directly relevant here, since chronically elevated cortisol drives insulin and IGF-1 signalling that keeps mTOR active and autophagic flux suppressed. Practitioners building longevity protocols will find the mTOR/AMPK/autophagy framework covered in detail in the autophagy, fasting, and longevity naturopathic clinical guide. For patients with high allostatic load requiring broad resilience support, ashwagandha also complements NAD+ precursor support for stress resilience and mitochondrial function — the approaches address different but overlapping aspects of cellular energy capacity under chronic stress conditions.

Beyond the mechanisms covered above, practitioners investigating adaptogenic peptide research compounds will find parallel areas of mechanistic overlap between peptide-based stress adaptation research and withanolide pathways — particularly in the domains of neuroprotection, inflammatory signalling, and HPA axis modulation.

3. Cortisol Reduction: Clinical Trial Evidence

The cortisol-lowering effect of ashwagandha is the most consistently replicated finding across its human RCT literature and arguably its most clinically important validated mechanism.

Chandrasekhar et al., 2012 (KSM-66)

The most cited RCT for ashwagandha's cortisol effects was published in the Indian Journal of Psychological Medicine (Chandrasekhar, Kapoor, and Anishetty). This was a double-blind, randomised, placebo-controlled trial in 64 adults with a history of chronic stress. Participants received 300 mg of KSM-66 ashwagandha root extract twice daily (600 mg/day total) or placebo for 60 days.

Key findings:

Serum cortisol reduced by 27.9% in the ashwagandha group versus 7.9% in placebo (p < 0.0001)
Perceived Stress Scale (PSS) scores reduced by 44% vs 5.5% in placebo
General Health Questionnaire (GHQ-28) scores significantly improved
Scores on the Depression, Anxiety and Stress Scale (DASS) improved across all three subscales
Food cravings (a cortisol-mediated appetite dysregulation marker) reduced significantly

This trial is methodologically sound — randomised, double-blind, placebo-controlled, with multiple validated psychological outcome measures alongside objective serum cortisol. The magnitude of cortisol reduction (approximately 28%) is clinically meaningful and substantially exceeds placebo response. The KSM-66 extract used is standardised to ≥5% withanolides by HPLC.

Pratte et al., 2014

A crossover trial (Journal of the International Society of Sports Nutrition) examined Sensoril ashwagandha at 250 mg/day and 500 mg/day in 98 adults over 60 days. Both doses produced significant reductions in PSS scores and self-reported stress. Serum cortisol was not the primary endpoint in this trial, but biochemical stress markers including C-reactive protein showed dose-dependent reduction, consistent with the anti-inflammatory mechanism discussed in Section 2.

The crossover design with a wash-out period strengthens internal validity. Notably, the 250 mg/day dose (lower than many commercial products) still produced statistically significant benefits, suggesting dose-response may plateau at moderate levels for psychological stress outcomes.

Auddy et al., 2008 (Sensoril)

Published in the Journal of the American Nutraceutical Association, this RCT examined Sensoril ashwagandha (a whole-plant extract standardised to ≥10% withanolides + ≥32% oligosaccharides) at three doses (125, 250, and 500 mg/day) versus placebo in 130 chronically stressed adults over 60 days.

Key cortisol findings:

All three active doses produced statistically significant serum cortisol reduction versus placebo
The 500 mg/day dose produced approximately 30% cortisol reduction
DHEA-S — the adrenal androgen that tends to be inversely depressed when cortisol is chronically elevated — increased significantly in the ashwagandha groups, particularly at 500 mg/day

The DHEA-S finding is clinically important. Chronic HPA axis hyperactivation suppresses DHEA-S production via precursor shunting toward cortisol synthesis. A compound that simultaneously reduces cortisol and restores DHEA-S suggests genuine HPA axis normalisation rather than simple cortisol suppression — the latter would not restore DHEA-S. This is consistent with the upstream HPA modulation mechanism rather than peripheral cortisol clearance effects.

Summary of cortisol evidence: Three independent RCTs, two standardised extracts, consistent serum cortisol reductions of 25–30% versus placebo over 60 days. The evidence for ashwagandha's cortisol-lowering effect is among the strongest in the botanical medicine literature.

4. Testosterone and Male Reproductive Health

Ashwagandha's effects on male reproductive parameters — testosterone, sperm quality, and fertility markers — are supported by several well-designed RCTs.

Ambiye et al., 2013

Published in Evidence-Based Complementary and Alternative Medicine, this double-blind RCT enrolled 46 male patients with oligospermia (low sperm count) and treated them with KSM-66 ashwagandha root extract 675 mg/day (225 mg three times daily) or placebo for 90 days.

Findings:

Sperm concentration increased by 167% in the ashwagandha group versus 9% placebo
Sperm motility increased by 57% versus 9% placebo
Sperm volume increased by 53% versus placebo
Serum testosterone increased by 17% versus a 4% increase in placebo (statistically significant)
Serum LH increased significantly, consistent with HPG axis upregulation
Antioxidant markers (superoxide dismutase, catalase, vitamin C) improved in seminal plasma

The dramatic improvements in sperm parameters alongside testosterone and LH increases are mechanistically coherent: reduced oxidative stress in the testes, restored HPG axis signalling, and improved Leydig and Sertoli cell function operating in concert. For practitioners managing male factor infertility, this trial offers substantial clinical justification for ashwagandha as an adjunctive intervention.

Wankhede et al., 2015

A key study for practitioners working with athletic performance and body composition (Journal of the International Society of Sports Nutrition). This double-blind RCT enrolled 57 young male adults (18–50) in an 8-week resistance training programme, randomised to KSM-66 300 mg twice daily or placebo.

Testosterone and strength findings:

Serum testosterone increased by 96.2 ng/dL in the ashwagandha group versus 18.0 ng/dL in placebo (statistically significant, p < 0.0001)
Muscle strength (1-RM bench press and leg extension) significantly greater in ashwagandha group
Muscle recovery (as assessed by serum creatine kinase — a marker of exercise-induced muscle damage) was significantly lower in ashwagandha group
Body composition: significantly greater increase in muscle mass and greater reduction in body fat percentage
Testosterone elevations correlated with the anabolic strength outcomes

In healthy men without oligospermia, the testosterone effect is more modest than in the Ambiye fertility study — approximately 15–17% increase from baseline. This is clinically meaningful but should be contextualised: it reflects restoration toward optimal physiological range, not pharmacological supraphysiologic elevation. This distinction is important for patient education, particularly for those who may have unrealistic expectations based on comparisons with anabolic steroid effects.

Mechanisms in Context

The consistent LH elevation seen across ashwagandha testosterone trials points to HPG axis restoration as the primary mechanism. In stressed or reproductively impaired men, cortisol-mediated GnRH suppression reduces LH drive. By reducing HPA axis burden, ashwagandha restores GnRH pulsatility and downstream LH secretion — a mechanism fundamentally different from exogenous testosterone administration and with a superior risk profile. FSH normalisation supports Sertoli cell function, explaining the concurrent improvements in sperm quality seen in fertility studies.

5. Thyroid Function

Ashwagandha's effects on thyroid hormones represent an area of genuine clinical promise, particularly for patients with subclinical hypothyroidism — a condition frequently encountered in naturopathic practice that conventional medicine often defers treating until TSH exceeds 10 mIU/L.

Gannon et al., 2014

A pilot double-blind RCT published in the Journal of Alternative and Complementary Medicine examined ashwagandha in 50 patients with subclinical hypothyroidism (elevated TSH with normal or low-normal T3 and T4) over 8 weeks using 600 mg/day of ashwagandha root extract.

Findings:

Serum T3 increased significantly (p = 0.0098) versus placebo
Serum T4 increased significantly (p = 0.0096) versus placebo
TSH reduced toward normal range, consistent with improved thyroid hormone feedback
No significant adverse effects reported

The clinical implication: in patients with subclinical hypothyroidism presenting with fatigue, cold intolerance, weight gain, or cognitive slowing where conventional intervention is not yet warranted, ashwagandha may provide measurable thyroid support while addressing the concurrent HPA axis dysregulation that frequently accompanies thyroid insufficiency.

For practitioners seeking to objectively characterise a patient's cortisol pattern before initiating ashwagandha — including diurnal free cortisol, the cortisol awakening response, and total cortisol metabolites — the DUTCH test provides the most comprehensive non-invasive HPA axis assessment available, and can serve as a useful baseline and treatment-monitoring tool.

Critical caution: hyperthyroidism. Ashwagandha's TSH-sensitising and T4→T3 conversion-enhancing effects make it contraindicated or requiring very careful monitoring in patients with hyperthyroidism, Graves' disease, or toxic thyroid nodules. Case reports document worsening of hyperthyroid symptoms following ashwagandha use. Additionally, in patients on levothyroxine (T4 replacement), enhanced T4→T3 conversion could produce supra-therapeutic T3 levels if the dose is not reviewed — thyroid function monitoring within 6–8 weeks of commencing ashwagandha is advisable in patients on thyroid medication.

For TGA-listed thyroid support products in Australia, practitioners should review the full ingredient list for concurrent iodine or selenium content, which may interact additively with ashwagandha's thyroid effects.

6. Cognitive Function and Neuroprotection

Ashwagandha's neuroprotective and cognitive effects are increasingly well-characterised in human clinical trials, moving this domain beyond preclinical inference.

Choudhary et al., 2017

Published in the Journal of Dietary Supplements, this double-blind RCT examined KSM-66 ashwagandha at 300 mg twice daily in 50 adults with mild cognitive impairment (MCI) over 8 weeks.

Key findings:

Immediate and general memory (Wechsler Memory Scale) improved significantly
Executive function and information processing speed improved
Montreal Cognitive Assessment (MoCA) scores improved by a mean of 1.8 points — clinically meaningful given the 2-point MCI-to-normal threshold
Sustained attention and information processing tasks showed significant improvement
Participants rated their overall wellbeing, alertness, and cognitive clarity higher

The MoCA improvement is particularly noteworthy for practitioners working with patients in the early-to-moderate cognitive decline range, where pharmacological options are limited and often poorly tolerated.

Mechanisms of Cognitive Benefit

Several mechanistic pathways plausibly explain ashwagandha's cognitive effects:

BDNF upregulation: Withanolide A has demonstrated brain-derived neurotrophic factor (BDNF) upregulation in animal studies, with hippocampal neurogenesis effects. Chronic stress is a well-established BDNF suppressor via cortisol-mediated glucocorticoid receptor activation in the hippocampus — ashwagandha's cortisol-lowering effects may restore BDNF expression secondarily.

Acetylcholine signalling: Ashwagandha inhibits acetylcholinesterase (AChE) in vitro, with withanolide A identified as the primary AChE-inhibiting constituent. Reduced ACh degradation supports cholinergic neurotransmission — the system targeted by pharmaceutical AChE inhibitors in Alzheimer's treatment. This effect appears modest at physiological doses but may be clinically relevant in the context of age-related cholinergic decline.

Oxidative neuroprotection: The brain is disproportionately vulnerable to oxidative damage given its high oxygen consumption and relatively modest antioxidant capacity. Withanolides' documented antioxidant activity — including superoxide dismutase and glutathione peroxidase upregulation — provides a neuronal protective effect that supports long-term cognitive resilience.

Cortisol-mediated hippocampal protection: Perhaps the most clinically straightforward neuroprotective mechanism: by reducing chronic cortisol exposure, ashwagandha limits the hippocampal volume loss and neuronal dendritic retraction that are documented consequences of sustained glucocorticoid excess. In patients with longstanding chronic stress and emerging cognitive symptoms, this is a central mechanistic rationale.

7. Athletic Performance

The Wankhede 2015 study described in Section 4 is the key RCT for athletic performance applications. Beyond testosterone and muscle mass outcomes, this trial also documented:

VO2max increased by 4.91 mL/kg/min in the ashwagandha group versus 1.42 mL/kg/min in placebo over 8 weeks of resistance training — a meaningful cardiorespiratory fitness improvement attributable to ashwagandha
Recovery: Serum creatine kinase (a marker of exercise-induced muscle damage) was significantly lower in the ashwagandha group at multiple post-training time points, suggesting enhanced muscle repair capacity

A separate study by Slaght and colleagues (2023, Journal of Exercise and Nutrition) examined ashwagandha in recreational runners and found improvements in time-to-exhaustion and self-reported recovery quality at 500 mg/day over 12 weeks.

The athletic performance evidence is most robust for:

Resistance-trained males — muscle strength, mass, and testosterone gains (Wankhede 2015)
Aerobic capacity — VO2max improvements in the context of structured training
Recovery — reduced post-exercise muscle damage markers, facilitating higher training frequency or intensity

For practitioners working with athletic patients, ashwagandha is one of the few botanical adaptogens with RCT evidence for objective performance outcomes — not just subjective wellbeing measures. Practitioners choosing between adaptogens should also review rhodiola rosea's distinct monoaminergic mechanism and RCT evidence for fatigue and cognitive performance, which offers a complementary activating profile suited to cognitively impaired or burned-out patients who need mental sharpening rather than cortisol suppression. Where mood symptoms and neurotransmitter insufficiency occur alongside impaired methylation — given that SAMe is required for serotonin and dopamine synthesis — assessment of MTHFR variants and methylation pathway status may identify an upstream driver that adaptogenic support alone will not resolve.

8. KSM-66 vs Sensoril vs Standard Extract: What to Prescribe

The clinical trial evidence for ashwagandha is predominantly derived from two standardised proprietary extracts: KSM-66 (Ixoreal Biomed) and Sensoril (Natreon Inc.). Practitioners prescribing or recommending ashwagandha should understand the differences.

KSM-66

Source: Root extract only, produced via a proprietary extraction process using whole milk as a carrier solvent (consistent with traditional Ayurvedic preparation)
Withanolide standardisation: ≥5% withanolides by HPLC
Evidence base: Majority of the testosterone, fertility, strength, and cognitive RCTs (Chandrasekhar 2012, Ambiye 2013, Wankhede 2015, Choudhary 2017)
Dosing in trials: 300 mg twice daily (600 mg/day) most common; some trials use 675 mg/day
Clinical application: Preferred for testosterone support, male fertility, athletic performance, and cognitive enhancement — the domains with the most KSM-66–specific trial data
Available in Australia: Yes, widely available in practitioner brands and retail products

Sensoril

Source: Whole-plant extract (root and leaf), producing a broader withanolide and oligosaccharide profile
Withanolide standardisation: ≥10% withanolides + ≥32% oligosaccharides
Evidence base: Auddy 2008 (cortisol, DHEA-S), Pratte 2014 (stress, inflammation)
Dosing in trials: 125–500 mg/day; lower doses effective for stress outcomes
Clinical application: Effective at lower absolute doses, making it well-suited for patients requiring cortisol and stress management where cost or tolerability at higher doses is a concern; some practitioners prefer it for anxious patients given the broader withanolide profile
Available in Australia: Available through specialist naturopathic suppliers and some health food retailers

Standard (Unstandardised) Extracts

Ashwagandha products that do not specify withanolide content or standardisation method should be approached with caution. Withanolide content in unstandardised root powder can vary by 5–10 fold between batches. For clinical applications where reproducible dosing is required, standardised extracts (KSM-66 or Sensoril) are preferable.

Dosing Summary

| Indication | Extract | Dose | Timing | |---|---|---|---| | Cortisol / stress | KSM-66 or Sensoril | 300–600 mg KSM-66 or 250–500 mg Sensoril | Once or twice daily with meals | | Testosterone / fertility | KSM-66 | 600–675 mg/day | Divided doses, with food | | Athletic performance | KSM-66 | 600 mg/day | Split morning/evening | | Cognitive function | KSM-66 | 600 mg/day | Morning dose preferred | | Thyroid (subclinical hypo) | Either | 600 mg/day | Consistent daily timing |

Onset of effects: Most RCTs demonstrate meaningful outcomes at 8 weeks minimum. Subjective stress and sleep improvements may emerge within 2–4 weeks (consistent with GABA-mimetic and early HPA modulation). Testosterone and sperm parameter improvements require 8–12 weeks of consistent use. Cognitive effects in the Choudhary trial were significant at 8 weeks.

Timing: No strong pharmacokinetic evidence mandates a specific time of day. Many practitioners split the dose morning/evening. Some patients report better sleep when taking the evening dose 30–60 minutes before bed, potentially related to GABAergic effects.

9. Safety, Contraindications, and Drug Interactions

Ashwagandha has a well-characterised safety profile across multiple clinical trials, with most adverse events being mild and transient.

General Tolerability

Across published RCTs using KSM-66 and Sensoril at doses of 300–1,250 mg/day over 8–12 weeks, the adverse event profile has been comparable to placebo. The most commonly reported effects are:

GI discomfort (nausea, loose stools) — typically dose-related and resolved by taking with food
Drowsiness — reported in a minority of participants, likely reflecting GABAergic activity; clinically manageable by shifting to evening dosing
Headache — infrequently reported, generally transient

No serious adverse events have been attributed to ashwagandha in any published RCT at standard doses.

Contraindications and Cautions

Pregnancy: Ashwagandha is contraindicated in pregnancy. Traditional Ayurvedic texts categorise it as an abortifacient at higher doses. Animal studies support uterotonic effects. Until human safety data in pregnancy is established, avoidance is strongly recommended.

Autoimmune conditions: The immune-modulating and NF-kB inhibitory effects theoretically warrant caution in patients with autoimmune disease on immunosuppressive therapy. No clinical adverse event data exists, but the interaction is plausible.

Hyperthyroidism: As detailed in Section 5, ashwagandha's thyroid-stimulating effects contraindicate use in hyperthyroid states.

Surgery: Withanolides may have mild anti-platelet activity. Discontinuation 2 weeks prior to elective surgery is a reasonable precaution, consistent with general botanical medicine peri-operative protocols.

Drug Interactions

Thyroid medications: In patients on levothyroxine (T4), ashwagandha's enhancement of T4→T3 conversion may produce supraphysiologic T3 levels. Thyroid function testing 6–8 weeks after commencing ashwagandha is advisable. Dose review with the prescribing GP or endocrinologist is warranted if TSH suppression occurs.

Sedatives and anxiolytics: Ashwagandha's GABAergic and CNS-calming effects may synergise with benzodiazepines, z-drugs, and other sedative medications. Caution regarding additive sedation is appropriate, particularly at higher doses or evening administration. This interaction is generally clinically manageable rather than an absolute contraindication.

Antidepressants: No pharmacokinetic drug interactions between ashwagandha and SSRIs or SNRIs have been established in human data. The pharmacodynamic question of combining GABAergic/cortisol-lowering effects with antidepressants is clinically reasonable; some naturopathic practitioners use ashwagandha as an adjunct in patients on antidepressant therapy for the stress and cortisol component. Patients should disclose to their prescribing physician if using ashwagandha alongside antidepressants.

Immunosuppressants: Theoretical reduction in immunosuppressant efficacy via immune-modulating mechanisms. Avoid concurrent use or monitor closely in patients on tacrolimus, cyclosporine, or corticosteroid immunosuppression.

Rare Hepatotoxicity Reports

A small number of case reports documenting cholestatic liver injury temporally associated with ashwagandha use have been published since 2020. These reports describe a pattern of jaundice, elevated transaminases, and cholestasis arising within 1–12 weeks of initiating ashwagandha, resolving on cessation. The mechanism is not established — it may reflect idiosyncratic withanolide metabolism in susceptible individuals.

These reports are rare relative to the widespread use of ashwagandha globally. However, practitioners should:

Take a complete supplement history in patients presenting with abnormal liver function tests
Counsel patients to report any onset of jaundice, pale stools, dark urine, or right upper quadrant pain
Avoid prescribing ashwagandha in patients with pre-existing hepatic impairment until further safety data emerges
Consider baseline LFTs in patients with hepatic risk factors prior to commencing supplementation

The hepatotoxicity signal does not negate ashwagandha's favourable overall safety profile at population level, but it warrants informed consent and appropriate monitoring in practice.

10. Frequently Asked Questions

What is the best dose of ashwagandha for cortisol reduction?

The most robust cortisol RCT data (Chandrasekhar 2012) used 600 mg/day of KSM-66 extract (300 mg twice daily) for 60 days, achieving approximately 28% cortisol reduction. The Auddy 2008 Sensoril trial found significant effects at 250–500 mg/day. For cortisol as the primary indication, 300–600 mg/day of KSM-66 or 250–500 mg/day of Sensoril over a minimum of 8 weeks represents the evidence-anchored prescribing range. Higher doses are not meaningfully supported by superior trial outcomes and increase the likelihood of GI side effects.

How long does ashwagandha take to work?

Onset depends on the outcome being targeted. Subjective stress, anxiety, and sleep improvements may emerge within 2–4 weeks, consistent with early GABAergic and HPA modulation effects. Serum cortisol changes require 4–8 weeks of consistent supplementation. Testosterone and male fertility parameters require 8–12 weeks. Cognitive improvements in the Choudhary 2017 MCI trial were significant at 8 weeks. A minimum trial duration of 8 weeks is appropriate before assessing treatment response; 12 weeks is preferable for reproductive and cognitive endpoints.

Can ashwagandha be taken with antidepressants?

No clinically established pharmacokinetic interaction between ashwagandha and SSRIs or SNRIs exists in the published literature. Many integrative practitioners use ashwagandha as an adjunct for stress and cortisol management in patients already on antidepressant therapy, particularly where HPA axis dysregulation is a significant contributor to the clinical picture. However, patients should inform their prescribing doctor, and monitoring for additive sedation (particularly if on sedating antidepressants such as mirtazapine) is appropriate. Ashwagandha is not a substitute for pharmacological antidepressant treatment.

Is KSM-66 better than Sensoril?

Neither extract is categorically superior — they have different evidence bases, extraction profiles, and optimal dosing ranges. KSM-66 (root-only, ≥5% withanolides) has more RCT data for testosterone, fertility, athletic performance, and cognitive outcomes. Sensoril (whole-plant, ≥10% withanolides) is effective at lower doses for cortisol and stress management and may suit patients requiring a more economical dosing strategy. Clinically, the choice should follow the primary indication: KSM-66 for reproductive, athletic, or cognitive targets; either extract for cortisol and stress management.

Can women take ashwagandha?

Yes — ashwagandha is appropriate for women outside of pregnancy and breastfeeding. The cortisol-lowering, anti-inflammatory, cognitive, and thyroid-supporting effects are not sex-specific. Women with adrenal fatigue presentations, subclinical hypothyroidism, or cognitive complaints from chronic stress represent appropriate candidates. The testosterone-supporting effects are less studied in women but are not a contraindication — physiological testosterone in women is relevant to libido, muscle function, and bone density, and ashwagandha's HPG axis effects at these doses are unlikely to produce androgenic adverse effects. Ashwagandha is contraindicated in pregnancy — this point requires clear patient communication.

Key Clinical Takeaways

Ashwagandha's clinical evidence base in 2026 supports the following practitioner-level conclusions:

Cortisol reduction is the best-replicated human RCT finding — approximately 25–30% serum cortisol reduction versus placebo over 60 days in three independent trials using two standardised extracts
DHEA-S restoration alongside cortisol reduction suggests genuine HPA axis normalisation, not peripheral cortisol suppression
Testosterone and male fertility improvements are well-supported — 15–17% testosterone increase, significant LH elevation, and dramatic sperm parameter improvements in fertility-impaired men (Ambiye 2013)
Thyroid support in subclinical hypothyroidism is supported by a pilot RCT; requires caution and monitoring in patients on thyroid medication
Cognitive benefits including improved MoCA scores and memory indices are demonstrated over 8 weeks in mild cognitive impairment
Athletic performance — VO2max, strength, muscle mass, and recovery — is supported by a well-designed crossover RCT (Wankhede 2015)
KSM-66 at 600 mg/day or Sensoril at 250–500 mg/day represent the evidence-anchored prescribing ranges; minimum 8-week trial required
Safety is generally excellent; the rare hepatotoxicity signal warrants informed consent and monitoring in at-risk patients
Pregnancy is an absolute contraindication; thyroid medication interaction requires function monitoring

For naturopathic practitioners, ashwagandha is one of the most comprehensively evidenced botanical adaptogens available — offering clinically meaningful effects across HPA axis, HPG axis, cognitive, and thyroid domains with a well-characterised safety profile and rational mechanistic framework.

References: Chandrasekhar et al., Indian Journal of Psychological Medicine (2012); Ambiye et al., Evidence-Based Complementary and Alternative Medicine (2013); Wankhede et al., Journal of the International Society of Sports Nutrition (2015); Auddy et al., Journal of the American Nutraceutical Association (2008); Pratte et al., Journal of the International Society of Sports Nutrition (2014); Choudhary et al., Journal of Dietary Supplements (2017); Gannon et al., Journal of Alternative and Complementary Medicine (2014). References available in full on request.